Plus therapeutics announces summary of fda meeting on company's cgmp manufacturing process for lead drug candidate

Cgmp production of 186 rnl targeted radiotherapeutic beginning in second half of 2022 to support ongoing and future respect™ clinical trials
pstv Ratings Summary
pstv Quant Ranking